ArticleAMB Express2026
Phage Henu15-resistant mutant derives fitness trade-offs in Morganella morganii.
Article in AMB Express, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The rapid emergence of multidrug-resistant strains of Morganella necessitates new therapeutic approaches, such as phage therapy. Phages are considered a promising adjunct to antibiotics. However, the rapid emergence of phage-resistant bacterial mutants poses a significant challenge in clinical practice. Nevertheless, this phenomenon is often accompanied by fitness trade-offs. Therefore, understanding these fitness trade-offs is crucial prior to phage clinical application. In the present study, a new lytic Morganella morganii phage, named Henu15, was isolated and characterized. The phage genome comprises a 52,795 bp double-stranded DNA with 72 open reading frames. Notably, the phage genome lacks genes encoding integrases, known virulence factors, or acquired antibiotic resistance determinants, underscoring its therapeutic potential. A time-kill assay demonstrated that Henu15 exhibits synergistic effects with ciprofloxacin, norfloxacin, and ceftazidime. Importantly, a Henu15-resistant mutant exhibited pleiotropic defects, including impaired adsorption, enhanced sensitivity to polymyxin B and tetracycline, reduced biofilm formation, and diminished in vivo colonization capacity. Through the whole-genome resequencing of the phage-resistant mutant, mutations were found in 7 genes involved in encoding related proteins such as ATP-dependent chaperone protein ClpB, tetrasulfate reductase subunit A, and AlpA family transcriptional regulators, which might be responsible for the observed fitness defects, providing a molecular basis for the attenuated virulence. Together, these findings provide new insights into the evolutionary interactions between phage resistance and bacterial fitness that could potentially offer a novel approach to treating resistant Morganella infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.